Search Results - molecule

11 Results Sort By:
Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers
The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...
Published: 10/28/2024   |   Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao
Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance
This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...
Published: 10/28/2024   |   Inventor(s): Jian-kang Jiang, Craig Thomas
Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials
Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1
This technology includes the use of novel lactate dehydrogenase (LDH) inhibitors, including WO2018005807A1, for the treatment of primary hyperoxalurias (PHs). PHs are rare autosomal recessive disorders caused by overproduction of oxalate, leading to recurrent calcium oxalate kidney stone disease, and in some cases end-stage renal disease. One potential...
Published: 10/28/2024   |   Inventor(s): Daniel Urban, Leonard Neckers, Ross Holmes, David Wood, Matthew Hall
Keywords(s): DEHYDROGENASE, Hyperoxalurias, Inhibitors, LACTATE, MOLECULE, Primary, Small, TREATING, VPXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Cardiology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Research Materials
Small Molecule Inhibitors of the p53/S100B Interaction for Treating Cancer
This technology includes newly identified best-in-class inhibitors of the p53-S100B interaction that plays a role in malignant melanoma. S100B contributes to cancer cell proliferation (particularly malignant melanoma) by binding to p53 and inhibiting its tumor suppressor function. A high-throughput screen was used to find p53-S100B inhibitors, leading...
Published: 10/28/2024   |   Inventor(s): Anton Simeonov, David Maloney, Daniel Jansen, Hongmao Sun, Diane Luci, Ajit Jadhav, Stephen Kales
Keywords(s): Inhibitors, MOLECULE, P53-S100B, Small, VCXXXX, WKXXXX, XEXXXX
Category(s): Application > Therapeutics, TherapeuticArea > Oncology
Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors
Aldehyde dehydrogenase enzymes (ALDHs) have a broad spectrum of biological activities through the oxidation of both endogenous and exogenous aldehydes. Unbalanced biological activity of ALDHs has been associated with a variety of disease states such as alcoholic liver disease, Parkinson’s disease, obesity, and Cancer. Increased expression of ALDH1A1...
Published: 10/28/2024   |   Inventor(s): Anton Simeonov, David Maloney, Natalia Martinez, Adam Yasgar, Shyh-Ming Yang
Keywords(s): 1A1, 3D spheroid, ALDEFLUOR assay, Aldehyde, ALDH, ALDH1A1, cancer stem cells, combined treatment, DEHYDROGENASE, high-content imaging, high-throughput screening, Inhibitors, liver, METABOLIC, MOLECULE, OBESITY, OV-90, Parkinson, RESISTANT, SKOV-3, Small
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning
This technology relates to the field of radioactive, isotopically-labeled calcofluor derivatives and uses of such compounds to detect a broad spectrum of filamentous fungi including pathogenic species such as Aspergillus and Mucorales, by diagnostic imaging methods such as positron emission tomography (PET) scanning. Aspergillosis and other filamentous...
Published: 10/28/2024   |   Inventor(s): Dale Kiesewetter, John Panepinto, Jin Qiu, Peter Williamson
Keywords(s): DA1XXX, FUNGI, IMAGING, Listed LPM Fenn as of 4/15/2015, MOLECULE, PET, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SCANNING, Small, VKXXXX, WBXXXX, XFXXXX, YCXXXX
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Medical Devices, Application > Software / Apps, Application > Diagnostics, Application > Non-Medical Devices
Diagnostic Assays and Methods of Use for Detection of Filarial Infection
The effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult Wuchereria bancrofti (Wb) antigen in blood, but...
Published: 10/28/2024   |   Inventor(s): Doran Fink, Joseph Kubofcik, Peter Burbelo, Thomas Nutman
Keywords(s): Bancrofitan, Bancrofti, CONTROL, DA2XXX, DAXXXX, DXXXXX, Filariasis, FOLLOWING, Immunodiagnosis, Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi), MOLECULE, Programs, Specific, Successful, Surveillance, Wuchereria
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Diagnostics
Pyruvate Kinase M2 Activators for the Treatment of Cancer
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...
Published: 10/28/2024   |   Inventor(s): Min Shen, Craig Thomas, Douglas Auld, Matthew Boxer
Keywords(s): [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...
Published: 10/28/2024   |   Inventor(s): Craig Thomas
Keywords(s): 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines
This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. PA is a secreted, non-toxic protein with a molecular weight of 83 KDa. PA is a major component of the currently licensed human vaccine (Anthrax Vaccine Adsorbed, AVA). Although the licensed human vaccine has been shown to be effective...
Published: 10/28/2024   |   Inventor(s): John Robbins, Stephen Leppla, Rachel Schneerson, M Rosovitz
Keywords(s): Anthrax, ANTIGEN, Chromosome 18 ring, Chymotrypsin-Sensitive, CREATION, Cutaneous anthrax, DAXXXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DELETIONS, DXXXXX, Furin-Cleavage..., Loop, MOLECULE, Protective, R 18, recombinant, rPA, STABLE, UAXXXX
Category(s): Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines
1 2